Abstract
The nucleocapsid protein (NP) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contains immunogenic epitopes that can induce cytotoxic T lymphocyte (CTL) against viral infection. This makes the nucleocapsid protein a suitable candidate for developing a vaccine against SARS-CoV-2 infection. This article reports the intradermal delivery of NP antigen using dissolvable microneedle skin patches that could induce both significant B cell and T cell responses.
Copyright © 2021 Chaiyaporn Kuwentrai et al.
MeSH terms
-
Animals
-
Antibodies, Viral / blood*
-
B-Lymphocytes / immunology
-
COVID-19 / prevention & control*
-
COVID-19 Vaccines / administration & dosage
-
COVID-19 Vaccines / immunology*
-
Coronavirus Nucleocapsid Proteins / administration & dosage
-
Coronavirus Nucleocapsid Proteins / immunology*
-
Enzyme-Linked Immunosorbent Assay
-
Injections, Intradermal / methods
-
Mice
-
Mice, Inbred BALB C
-
Phosphoproteins / administration & dosage
-
Phosphoproteins / immunology
-
SARS-CoV-2 / immunology*
-
T-Lymphocytes, Cytotoxic / immunology*
Substances
-
Antibodies, Viral
-
COVID-19 Vaccines
-
Coronavirus Nucleocapsid Proteins
-
Phosphoproteins
-
nucleocapsid phosphoprotein, SARS-CoV-2